Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
SK: Conceptualization, Methodology, Software, Formal Analysis, Visualization, Investigation, Writing original draft, Writing review and editing
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
GLP-1s arent safe for everyone
Clinical trials show oral semaglutide produces 10-15% weight loss, compared to 15-22% for the same dose injected, a meaningful difference over a year of treatment
Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 related to the Companys previously announced voluntary pause
Smaller changes do not necessarily mean the medication is not working
US$ 24.31
US$ 23.83
US$ 22.00
US$ 20.94
US$ 25.73
US$ 28.34
US$ 29.74
US$ 26.87
